EA201691924A1 - Фармацевтические композиции - Google Patents

Фармацевтические композиции

Info

Publication number
EA201691924A1
EA201691924A1 EA201691924A EA201691924A EA201691924A1 EA 201691924 A1 EA201691924 A1 EA 201691924A1 EA 201691924 A EA201691924 A EA 201691924A EA 201691924 A EA201691924 A EA 201691924A EA 201691924 A1 EA201691924 A1 EA 201691924A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
application describes
precisely
preparation
pharmaceutical composition
Prior art date
Application number
EA201691924A
Other languages
English (en)
Other versions
EA036278B1 (ru
Inventor
Доменико Фанара
Джонатан Гул
Мишель Делер
Original Assignee
Юсб Фархим С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Фархим С.А. filed Critical Юсб Фархим С.А.
Publication of EA201691924A1 publication Critical patent/EA201691924A1/ru
Publication of EA036278B1 publication Critical patent/EA036278B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описана фармацевтическая композиция, содержащая левоцетиризин. Точнее, в заявке описан препарат, представляющий собой сухой сироп.
EA201691924A 2014-03-27 2015-03-26 Фармацевтическая композиция EA036278B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162001 2014-03-27
EP14161997 2014-03-27
PCT/EP2015/056593 WO2015144830A1 (en) 2014-03-27 2015-03-26 Pharmaceutical compositions comprising levocetirizine

Publications (2)

Publication Number Publication Date
EA201691924A1 true EA201691924A1 (ru) 2017-02-28
EA036278B1 EA036278B1 (ru) 2020-10-21

Family

ID=52774233

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691924A EA036278B1 (ru) 2014-03-27 2015-03-26 Фармацевтическая композиция

Country Status (15)

Country Link
US (3) US20170105988A1 (ru)
EP (1) EP3122330B1 (ru)
JP (2) JP6506301B2 (ru)
KR (1) KR102445606B1 (ru)
CN (2) CN111632023A (ru)
BR (1) BR112016022126B1 (ru)
CA (1) CA2940920C (ru)
DK (1) DK3122330T3 (ru)
EA (1) EA036278B1 (ru)
ES (1) ES2691920T3 (ru)
HU (1) HUE039791T2 (ru)
MX (1) MX371443B (ru)
PL (1) PL3122330T3 (ru)
PT (1) PT3122330T (ru)
WO (1) WO2015144830A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
JP6986244B2 (ja) * 2017-09-27 2021-12-22 高田製薬株式会社 レボセチリジン固形製剤
MX2023003432A (es) * 2020-09-29 2023-08-04 Millicent Pharma Ltd Formulaciones orodispersables.
JP2023549381A (ja) 2020-11-18 2023-11-24 バイオファーマ・シナジーズ，エス．エル． 抗ヒスタミン活性化合物を含む口内分散性粉末組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
PL212123B1 (pl) * 2002-01-15 2012-08-31 Ucb Farchim Sa Doustna kompozycja farmaceutyczna
US20060083786A1 (en) * 2004-07-29 2006-04-20 Glenmark Pharmaceuticals Limited Taste masking pharmaceutical composition containing levocetirizine
WO2008119033A1 (en) * 2007-03-27 2008-10-02 Eurand, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
US8298585B2 (en) * 2007-06-06 2012-10-30 Asahi Kasei Chemicals Corporation Cellulose-based fine core particle and process for producing the same
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
WO2011110939A2 (en) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
JP2013159587A (ja) * 2012-02-07 2013-08-19 Riken Vitamin Co Ltd レイヤリング用核粒子の製造方法
JP6176840B2 (ja) * 2012-06-29 2017-08-09 高田製薬株式会社 フェキソフェナジン顆粒製剤及びその製造方法
CN102860986A (zh) * 2012-09-28 2013-01-09 天津市聚星康华医药科技有限公司 一种稳定的掩味的左西替利嗪药物组合物及其制备方法

Also Published As

Publication number Publication date
WO2015144830A1 (en) 2015-10-01
BR112016022126B1 (pt) 2023-05-02
US20170105988A1 (en) 2017-04-20
ES2691920T3 (es) 2018-11-29
US20200297718A1 (en) 2020-09-24
PT3122330T (pt) 2018-11-13
CA2940920A1 (en) 2015-10-01
CA2940920C (en) 2023-08-29
JP6820116B2 (ja) 2021-01-27
MX371443B (es) 2020-01-30
HUE039791T2 (hu) 2019-02-28
CN111632023A (zh) 2020-09-08
JP2018184436A (ja) 2018-11-22
EP3122330B1 (en) 2018-07-25
CN106102715A (zh) 2016-11-09
US20210251984A1 (en) 2021-08-19
BR112016022126A2 (pt) 2021-08-03
KR20160137521A (ko) 2016-11-30
JP6506301B2 (ja) 2019-04-24
KR102445606B1 (ko) 2022-09-20
MX2016011401A (es) 2017-04-06
JP2017508761A (ja) 2017-03-30
EA036278B1 (ru) 2020-10-21
PL3122330T3 (pl) 2019-01-31
EP3122330A1 (en) 2017-02-01
DK3122330T3 (en) 2018-10-22

Similar Documents

Publication Publication Date Title
DK3529248T3 (da) Farmaceutiske sammensætninger
BR112018005750A2 (pt) composições para higiene bucal.
BR112016023628A2 (pt) composições farmacêuticas.
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
GEP20217239B (en) Pharmaceutical composition
BR112017004612A2 (pt) compostos, composição farmacêutica, usos de um composto, e kit
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
DK3325487T3 (da) Formulering til bløde, anticholinerge analoger
EP3160491A4 (en) Pharmaceutical compositions
GEP20217240B (en) Pharmaceutical composition
EP3278801A4 (en) Medicinal composition containing mirabegron
EP3218061A4 (en) Carmustine pharmaceutical composition
BR112017022439A2 (pt) composições para higiene bucal.
MA47516A (fr) Composition pharmaceutique
EA201691924A1 (ru) Фармацевтические композиции
EP3243510A4 (en) Sulfonamide pharmaceutical composition
EP3275457A4 (en) Pharmaceutical composition containing silybin
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
EP3191093A4 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM